Latest News-Shanghai Henlius Biotech, Inc. Mediaroom_Page

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it ...

2025-02-06 19:40 4595

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line tr...

2025-02-05 22:05 4720

Henlius and SVAX Forge Strategic Partnership in the MENAT Market

SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- On the morning of November 7, at the 7th China International...

2024-11-09 00:35 6751

Henlius and SVAX Forge Strategic Partnership in the MENAT Market

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

* HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SC...

2024-09-21 13:42 6462

Henlius Trastuzumab Receives FDA Approval in the United States

SHANGHAI, April 29, 2024 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2024-04-29 20:18 4411

Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity

SHANGHAI, April 17, 2024 /PRNewswire/ -- On April 17, 2024, Henlius (2696.HK) released its 2023 Env...

2024-04-17 20:32 3191

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved

SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. Durin...

2024-03-21 19:47 5446

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Base...

2024-03-04 21:28 2652

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Base...

2024-03-04 21:19 3987

First International Shipment of HANSIZHUANG Launched

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying anti-PD-1 mAb Zerpidio® (se...

2024-01-25 21:41 3932

First International Shipment of HANSIZHUANG

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying HANSIZHUANG Zerpidio® (anti...

2024-01-25 20:45 6142

HANSIZHUANG Sets Sail in Indonesia Market

* The 1st China anti-PD-1 monoclonal antibody successfully approved in Southeast Asia - * The 1...

2023-12-28 21:51 5530

The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...

2023-12-12 20:30 3617

Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Henlius（2696.HK）announced its financial results and busines...

2023-11-15 20:16 4261

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA

* HANSIZHUANG's coverage footprint includes 22 emerging market countries acrossSoutheast Asia and...

2023-09-12 19:24 2234

Latest News

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Henlius and SVAX Forge Strategic Partnership in the MENAT Market

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Henlius Trastuzumab Receives FDA Approval in the United States

Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

First International Shipment of HANSIZHUANG Launched

First International Shipment of HANSIZHUANG

HANSIZHUANG Sets Sail in Indonesia Market

The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA

Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved

Henlius Announces NMPA Approvals of Two ADC Candidates for IND

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA